Report Overview

The global hepatitis therapeutics market size stood at around USD 21.73 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Based on the estimates of WHO, approximately 400 million people are infected with at least one form of hepatitis globally, and annually nearly 1.4 people die due to the condition. Some of the common symptoms of hepatitis are loss of appetite, nausea and vomiting, fatigue, fever, body aches, and stomach pain. Some people may experience light-coloured bowel movements, dark urine, and yellowing of the skin or of the eyes (jaundice).



Market Drivers

Increase in the prevalence of viral hepatitis, promising hepatitis drug pipeline, and favourable government support for creating awareness are the major drivers of the global market.

Major Hepatitis Disease

Hepatitis C Segment is expected to hold a major market share in the hepatitis therapeutics market. Hepatitis C is a liver infection which is caused by the hepatitis C virus. Hepatitis C can range from a mild to serious and lifelong illness. Hepatitis C segment holds a significant market share in the hepatitis therapeutics market and is anticipated to show a similar trend over the forecast period due to the high prevalence of hepatitis C in developing and developed regions and the growing availability of effective drug regimens in the market.